Compare PATH & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PATH | PRAX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 7.1B |
| IPO Year | 2021 | 2020 |
| Metric | PATH | PRAX |
|---|---|---|
| Price | $12.39 | $305.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 19 |
| Target Price | $15.41 | ★ $674.48 |
| AVG Volume (30 Days) | ★ 22.4M | 436.3K |
| Earning Date | 12-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 500.00 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,610,572,000.00 | N/A |
| Revenue This Year | $11.28 | N/A |
| Revenue Next Year | $8.25 | $55,143.56 |
| P/E Ratio | $119.55 | ★ N/A |
| Revenue Growth | ★ 12.65 | N/A |
| 52 Week Low | $9.20 | $160.11 |
| 52 Week High | $19.84 | $392.70 |
| Indicator | PATH | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 52.18 |
| Support Level | $10.58 | $281.96 |
| Resistance Level | $13.33 | $349.73 |
| Average True Range (ATR) | 0.49 | 19.86 |
| MACD | -0.05 | 3.54 |
| Stochastic Oscillator | 8.92 | 45.96 |
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies, including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries, including claims processing, employee onboarding, invoice-to-cash, loan applications, and customer service. The company works in the Americas, Europe, the Middle East, and Africa, and Asia-Pacific, with the maximum revenue from the America.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.